Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 6, 2015, Pages 1131-1137

  Ening, G ^a   Osterheld, F ^b   Capper, D ^c   Schmieder, K ^a   Brenke, C ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Age; Charlson comorbidity index; Glioblastoma; Karnofsky performance score; Overall survival; Progression free survival

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; COMORBIDITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEMOGRAPHY; DNA METHYLATION; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL STATUS; GENE MUTATION; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEURORADIOLOGY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SURVIVAL RATE; SYMPTOM; TERTIARY HEALTH CARE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; VOLUMETRY; BRAIN NEOPLASMS; DISEASE COURSE; DNA SEQUENCE; GENETICS; HEALTH STATUS INDICATOR; PATHOLOGY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMORBIDITY; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HEALTH STATUS INDICATORS; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 84929208533     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1907-9     Document Type: Article

References (29)

1. Asano K, Nakano T, Takeda T, Ohkuma H (2009) Risk factors for postoperative systemic complications in elderly patients with brain tumors. Clinical article. J Neurosurg 111:258–264. doi:10.3171/2008.10.17669
2. Balducci M et al (2012) Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol 29:3478–3483. doi:10.1007/s12032-012-0263-3
3. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14
4. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594. doi:10.3171/2010.8.JNS1081
5. Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2012) Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol 106:383–389. doi:10.1007/s11060-011-0676-4
6. Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2014) The relative value of postoperative versus preoperative Karnofsky performance scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol. doi:10.1007/s11060-014-1640-x
7. Chang SM et al (2003) Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J Neurosurg 98:1175–1181. doi:10.3171/jns.2003.98.6.1175
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
9. Chinot OL et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. doi:10.1056/NEJMoa1308345
10. Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.1056/NEJMoa1308573
11. Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. doi:10.3171/2014.7.JNS132449
12. Hartmann C et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146–5157. doi:10.1158/1078-0432.CCR-13-0017
13. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331
14. Hervey-Jumper SL, Berger MS (2014) Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol 16:284. doi:10.1007/s11940-014-0284-7
15. Johnson MJ, Bland JM, Davidson PM, Newton PJ, Oxberry SG, Abernethy AP, Currow DC (2014) The relationship between two performance scales: New York Heart Association classification and Karnofsky performance status scale. J Pain Symptom Manag 47:652–658. doi:10.1016/j.jpainsymman.2013.05.006
16. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34–40. doi:10.3171/jns.2006.105.1.34
17. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225 discussion 226–219
18. Lacroix M et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. doi:10.3171/jns.2001.95.2.0190
19. Louis DN et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4
20. Malmstrom A et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. doi:10.1016/S1470-2045(12)70265-6
21. Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A (2011) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428–430. doi:10.1111/j.1365-2990.2010.01127.x
22. Sanson M et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154. doi:10.1200/JCO.2009.21.9832
23. Shi WM, Wildrick DM, Sawaya R (1998) Volumetric measurement of brain tumors from MR imaging. J Neurooncol 37:87–93
24. Solheim O, Selbekk T, Jakola AS, Unsgard G (2010) Ultrasound-guided operations in unselected high-grade gliomas—overall results, impact of image quality and patient selection. Acta Neurochir (Wien) 152:1873–1886. doi:10.1007/s00701-010-0731-5
25. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330
26. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):93–101. doi:10.1093/annonc/mdu050
27. van den Bent MJ et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593. doi:10.1016/S1470-2045(11)70057-2
28. Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G (2010) Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncol 6:1407–1414. doi:10.2217/fon.10.113
29. Wick W et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715. doi:10.1016/S1470-2045(12)70164-X